Harris & Harris Group has always been actively involved in the life sciences. Over the past 10 years, within our focus on investing in technologies enabled at the nanoscale, the percentage of companies addressing needs in the life sciences that we have invested in has increased from 48 percent to greater than 67 percent. We believe this trend will continue because of the opportunities that will exist in the life sciences over the coming decades.
READ MORE
Two weeks ago at the World Food Prize in Des Moines, Iowa, I was reminded of something my friend and former colleague, Dr. Chris Hartshorn, likes to say: “We need more surgeons and fewer patients.” Since the 2008 downturn, we have been inundated with people wanting to talk about all of the problems in the world. However, we have seen very few solutions to these problems. With the exception of Simpson-Bowles offering a reasonable start to solving the debt/growth challenge in the United States, there have been far too little alternatives offered to simply complaining about it being the other guy’s fault.
READ MORE
In his New York Times column of October 2, “More Money Than They Know What To Do With,” Andrew Ross Sorkin highlights an upcoming challenge facing the private equity industry: If the current glut of excess capital is not deployed over the coming 1-2 years, the money will need to be returned to investors.
An natural first reaction would be to think, “Fantastic, the market is short on capital, which has the potential to make a lot happen in a stagnant economy.” While this is certainly true, it is critical to ensure that capital gets deployed in a responsible way; otherwise, in five years investors very well might pick their heads up to realize they are sitting on a fraction of what they invested.
READ MORE
There is a fascinating bubble about to burst, but this one could be incredibly positive. Over the last decade large corporations have continued to accumulate massive cash balances, despite raising dividends to an all-time high according to S&P Dow Jones Indices.
READ MORE
Over the last few years, much has been written about the demise of the United States as an innovation engine.
READ MORE
Last week I had the distinct pleasure of attending the Lux Executive Summit in Boston. As many of you know, I was part of the initial team at Lux Research and have had the pleasure of attending 7 Summits. So, what did we find out?
READ MORE
As venture capital investors we are continuously thinking about the future. What breakthrough technologies we see today are going to be the necessities of tomorrow?
READ MORE
After spending 7 ½ years helping to build Lux Research, I’ve decided to enter the next phase of my career at Harris & Harris Group. I’ve been asked many times, “Why are you making the move?”
READ MORE
On January 17, 2012, Harris & Harris Group made its first foray into show business – well non-profit show business. We were asked to participate in a 3-5 minute educational segment discussing venture capital, entrepreneurship and nanotechnology that will air on Public Broadcasting Stations (PBS).
READ MORE
There are many adages in the early-stage venture capital business. One of them is to keep leading researchers, often the scientific founders of these early-stage companies, in their labs rather than having them join the start-up company.
READ MORE
Showing
0
-
10
( of
12
records)
Page:
1 2